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Background: Effect of dual antiplatelet treatment in post-MI survivor patients with age ≥65 years, diabetes, history of >1 MI, or renal 
disease as risk factors is studied in the PEGASUS-TIMI 54 trial*. The impact of these risk factors in unselected post-MI survivors has not 
been studied.
methods: A cohort study linked Swedish National registry data on morbidity, mortality and medication for patients with MI (NCT01984307). 
77,976 patients without a recurrent MI at one year were included. Risk factor impact on an endpoint of non-fatal MI, stroke or all cause 
death was estimated at third year of follow-up. Adjusted for age and sex; and for multiple risk factors.
results: In real life unselected post-MI survivor patients without recurrent MI at one year, age ≥ 65 years was most prevalent (70%) and 
impactful of the additional risk factors used in the PEGASUS trial (Table 1). Diabetes was common (23%), showing similar event rate (28%) 
as patients with a history of >1 MI (29%) at 3rd year of follow up. Patients with renal disease had a high event rate.
Conclusion:  Age is the most prevalent and important risk factor in post-MI survivor patients; higher in this real life clinical setting than in 
patients recruited in PEGASUS. Diabetes is common among post-MI survivors, showing an increased event rate versus non-diabetic MI 
patients and similar event rate as patients with a history of >1 MI. The present findings indicate the need for more careful monitoring and 
management of post-MI survivor patients with diabetes.
